

Amendments to the Specification:

Please delete the section entitled **CROSS-REFERENCE TO RELATED APPLICATIONS** on page 1, line 6-11 of the application.

Please insert the following section on page 1, at line 3 of the application (directly after the title):

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of Provisional Application Serial No. 60/165,940, entitled "Disruption of EGFR Function through Expression of Dominant Negative EGFR-CD533 (or Other Inhibitors) as a Tool to Inhibit Carcinoma Cells' Proliferation in Response to Repeated Radiation Therapy Treatments and to Radiosensitize Such Cells," filed on November 17, 1999, which is herein incorporated by reference.